Grant ID DP220038
Awarded On August 17, 2022
Title Humanization, validation, and clinical translation of cell surface Heat shock protein 70-targeted antibody drug conjugates for T-cell non-Hodgkin lymphomas
Program Product Development Research
Award Mechanism Seed Awards for Product Development Research
Institution/Organization Asylia Therapeutics
Principal Investigator/Program Director John Miller
Cancer Sites Breast, Lymphoma, Myeloma
Contracted Amount $3,000,000*

*Pending contract negotiation

Lay Summary

Antibody-drug conjugates (ADCs) are an expanding class of highly effective cancer medicines. In ADCs, a toxic payload is conjugated to an antibody that recognizes a specific protein target selectively expressed on the surface of cancer cells. This results in the high concentration of toxin in tumors, while reducing toxicity to normal tissues. A long-sought goal has been to identify targets that are selectively expressed on the surface of a broad range of cancer but not normal cells. The scientific founders of Asylia discovered that the surface of many cancer cell types, but not normal cells, is decorated by Heat Shock Protein 70 (HSP70), where it can be targeted by antibodies loaded with can...

Read More